Psoriatic Arthritis

Top Story

Factors of methotrexate-induced epidermal necrosis identified

May 23, 2017

Researchers identified early signs and risk factors of methotrexate-induced epidermal necrosis, and physicians should use caution when deciding when to prescribe methotrexate to high-risk patients, according to recently published study results in the Journal of the American Academy of Dermatology.

The researchers in Taiwan enrolled 24 patients with methotrexate-induced epidermal necrosis (MEN; mean age, 65.8 years; 13 men) and 150 methotrexate-tolerant controls (mean age, 40.7 years; 86 men) between 2007 and 2016. Demographics, pathology and plasma concentration of methotrexate were analyzed.

In the Journals

Study finds patients with AS, PsA or uSpA had greater risks for acute coronary syndrome, stroke events

May 23, 2017
Patients with ankylosing spondylitis, psoriatic arthritis or undifferentiated spondyloarthritis had greater risks for acute coronary syndrome and stroke events compared…
Cover Story

Through the Cracks: Niche Patient Population Battles Dermatopathologic Complications of Rheumatic Disease

Healio Rheumatology, May 2017
Patients with serious skin complications associated with rheumatic diseases may face a host of obstacles. Misdiagnosis is common. They are treated with non-curative…
In the Journals

Patients with psoriasis treated with biologics have minimal risk of hepatitis B, C reactivation

May 18, 2017
Patients with moderate-to-severe psoriasis without hepatitis who were seropositive for hepatitis B core antibody only or hepatitis C infection, and who were being…
CME

Pediatric Rheumatology: June 2015

Keck School of Medicine of USC and Pediatric Annals

Of all the areas of pediatric practice, none can seem more daunting or require a higher index of suspicion than…
More »
Video
Meeting News Coverage

VIDEO: Fernandez speaks about TNF-induced psoriasis

August 16, 2016
More »
Featured
Osteoarthritis Research Society International World Congress

Osteoarthritis Research Society International World Congress

CME CNE CPE CE

The Management of Comorbid Conditions in Patients with Rheumatoid Arthritis

Supported by an educational grant from Pfizer Inc.

Strong evidence demonstrates that patients with rheumatoid arthritis (RA) are at a high risk for developing several…
More »
In the Journals

Factors of methotrexate-induced epidermal necrosis identified

May 23, 2017
Researchers identified early signs and risk factors of methotrexate-induced epidermal necrosis, and physicians should use caution when deciding when…

In the Journals

Study finds patients with AS, PsA or uSpA had greater risks for acute coronary syndrome, stroke events

May 23, 2017
Patients with ankylosing spondylitis, psoriatic arthritis or undifferentiated spondyloarthritis had greater risks for acute coronary syndrome and…

Cover Story

Through the Cracks: Niche Patient Population Battles Dermatopathologic Complications of Rheumatic Disease

Healio Rheumatology, May 2017
Patients with serious skin complications associated with rheumatic diseases may face a host of obstacles. Misdiagnosis is common. They are treated…

In the Journals

Patients with psoriasis treated with biologics have minimal risk of hepatitis B, C reactivation

May 18, 2017
Patients with moderate-to-severe psoriasis without hepatitis who were seropositive for hepatitis B core antibody only or hepatitis C infection, and…

In the Journals

Biosimilars unlikely to save costs as expected, experts say

May 4, 2017
Despite being heralded as lower-cost alternatives to branded biologics, the approval of biosimilar therapies for chronic diseases is not likely to…

FDA accepts review of supplemental new drug applications of Xeljanz, Xeljanz XR for psoriatic arthritis

May 3, 2017
The FDA has accepted to review the supplemental new drug applications of Xeljanz at 5 mg twice daily, as well as Xeljanz XR extended release at 11 mg…

In the JournalsPerspective

Psoriatic arthritis linked with diabetes, other endocrine disorders

April 25, 2017
Psoriatic arthritis was linked with diabetes, Cushing disease, hypothyroidism and osteoporosis, according to a recent analysis of Israeli patients…

Biosimilars to rituximab, etanercept recommended for approval in Europe

April 21, 2017
The Committee for Medicinal Products for Human Use has recommended approval of biosimilars by Sandoz for rituximab and etanercept for the same…

Editorial

Kinase Inhibition in Rheumatology: Cutting Edge of the Brave New World of Therapeutics

Healio Rheumatology, April 2017
Leonard H. Calabrese, DO
Yes, I started this Editorial by quoting myself — I do not think it is plagiarism as I am citing the source and I believe this is my quote. If…

Cover Story

What Rheumatologists Need to Know About Janus Kinase Inhibitors

Healio Rheumatology, April 2017
Janus kinase inhibitors have grown into a promising drug class for the treatment of rheumatoid arthritis, as these have an oral route of…

More Headlines »
Advertisement
Advertisement